Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale

Archives of Neurology

Volumn 65, Issue 11, 2008, Pages 1449-1453

  Bakshi, Rohit ^a,b   Neema, Mohit ^a   Healy, Brian C ^a   Liptak, Zsuzsanna ^b   Betensky, Rebecca A ^c   Buckle, Guy J ^a   Gauthier, Susan A ^a   Stankiewicz, James ^a   Meier, Dominik ^b   Egorova, Svetlana ^b   Arora, Ashish ^a   Guss, Zachary D ^a   Glanz, Bonnie ^a   Khoury, Samia J ^a   Guttmann, Charles R G ^a,b   Weiner, Howard L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADULT; ATROPHY; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 55949096821     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.11.1449     Document Type: Article

References (26)

1. Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging. 2005;15(4)(suppl):10S-21S.
2. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol. 2003;250(12):1407-1419.
3. Li DK, Held U, Petkau J, et al; Sylvia Lawry Centre for MS Research. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology. 2006;66(9):1384-1389.
4. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5(2):158-170.
5. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42(5):783-793.
6. Wolinsky JS, Narayana PA, Noseworthy JH, et al; MRI Analysis Center of the University of Texas-Houston, Health Science Center; North American Linomide Investigators. Linomide in relapsing and secondary progressive MS, part II: MRI results. Neurology. 2000;54(9):1734-1741.
7. Mainero C, De Stefano N, Iannucci G, et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology. 2001;56(10):1331-1334.
8. Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group; MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler. 2001;7(1):33-41.
9. Sriram S, Yao SY, Stratton C, Moses H, Narayana PA, Wolinsky JS. Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS. J Neurol Sci. 2005;234(1-2):87.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444- 1452.
11. Gauthier SA, Glanz BI, Mandel M, Weiner HL. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev. 2006;5(8):532-536.
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58(6):840-846.
13. Lublin FD, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-911.
14. Jacobs LD, Beck RW, Simon JH, et al; CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
15. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium (NYSMSC). Mult Scler. 1999;5(5):369-376.
16. Wei X, Warfield S, Zou KH, et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging. 2002;15(2):203-209.
17. Pelletier D, Garrison K, Henry R. Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimaging. 2004;14(3)(suppl):11S-19S.
18. Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci. 2003;208(1-2):57-65.
19. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126(pt 8):1782-1789.
20. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882.
21. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7(1):1-26.
22. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82(397):171-185.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Assoc; 1988.
24. Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol. 2007;62(3):219-228.
25. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68(9):634-642.
26. Tench CR, Morgan PS, Jaspan T, Auer DP, Constantinescu CS. Spinal cord imaging in multiple sclerosis. J Neuroimaging. 2005;15(4)(suppl):94S- 102S.